A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.

•This was the first and largest study focusing on prognosis model in LM of lung cancer patients.•EGFR/ALK positivity, KPS score≥60 and absence of ECM independently predict better OS in LM of lung cancer patients.•A novel LM molGPA model was established and internally validated to classify the heterogeneous patients.